敗血症診断市場の評価：製品・技術・手法・検査タイプ・病原体・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界の敗血症診断の市場規模は、2023年の8億米ドルから、2024年から2031年の予測期間中は8.7%のCAGRで推移し、2031年には15億6,000万米ドルの規模に成長すると予測されています。

市場の拡大は、敗血症関連の研究活動への投資の増加、敗血症症例の増加、感染症の蔓延の拡大、高度な診断ソリューションの開発、敗血症に関する認識を広めるためのさまざまな政府による取り組みの増加によって支えられています。

先進的な診断ソリューションの開発が重視されるようになった背景には、敗血症に関連する症例数の増加があります。米国Center for Disease Control and Prevention (CDC) によると、米国では毎年約170万人の成人が敗血症を発症し、およそ270万人が死亡しています。さまざまな大手医療診断企業や新興企業が、医療従事者の負担を軽減し、迅速かつ正確な結果を提供できる高度な診断ソリューションの開発に向けて積極的に取り組んでいます。

投資の増加が敗血症診断薬市場の拡大を支える

世界のさまざまな地域で敗血症の有病率が増加していることから、先進的な診断ソリューションの開発に対する大手参入企業による投資の増加が市場の発展を後押ししています。2023年、ハンドヘルドのポイントオブケア診断デバイスの開発に携わる革新的な企業であるProxim Diagnostics Corporationは、体外診断分野の世界的リーダーの1つであるBioMerieux SAから投資を受けています。

敗血症の有病率の上昇が市場需要を押し上げる

各地域における敗血症の有病率の増加は、市場に有利な成長機会をもたらすと期待されています。UK Sepsis Trustによると、英国だけで24万5,000人が敗血症に罹患しており、毎年約48,000人がさまざまな敗血症関連の疾患で命を落としています。敗血症に関連する発症の増加は、素因となる合併症の多い高齢化社会の拡大、侵襲的処置や医療機器の必要性の増加、多剤耐性病原体の蔓延、免疫抑制の頻繁な使用などに起因すると考えられています。この疾患は通常、寄生虫、細菌、ウイルス、真菌などによる感染に対して免疫系が過剰に反応することで発症します。免疫系は患者の臓器を攻撃し始め、臓器不全を引き起こします。

当レポートでは、世界の敗血症診断の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の敗血症診断市場の展望

• 市場規模・予測
• 製品別
  • 血液培養培地
  • アッセイキット・試薬
  • 機器
  • ソフトウェア
• 技術別
  • マイクロバイオロジー
  • 分子診断
  • 免疫学的検査
  • フローサイトメトリー
  • その他
• 手法別
  • 従来型
  • 自動化
• 検査タイプ別
  • 臨床検査
  • ポイントオブケア検査
• 病原体別
  • 真菌性敗血症
  • 細菌性敗血症
  • ウイルス性敗血症
  • その他
• エンドユーザー別
  • 診断センター
  • 病院・クリニック
  • 病理・リファレンスラボ
  • 研究および学術機関
  • その他
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界の敗血症診断市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• 製品別
• 技術別
• 手法別
• 検査タイプ別
• 病原体別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (主要企業)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Becton, Dickinson & Company
• BioMerieux SA
• F. Hoffmann-La Roche AG
• Luminex Corp.
• Thermo Fisher Scientific, Inc.
• Abbott Laboratories
• Danaher Corporation
• Bruker Corporation
• Cerner Corporation
• GE Healthcare

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 2.Global Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 3.Global Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 4.Global Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 5.Global Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 6.Global Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 7.Global Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 8.Global Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 9.Global Sepsis Diagnostics Market Share (%), By Region, 2017-2031F
• Figure 10.North America Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 11.North America Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 12.North America Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 13.North America Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 14.North America Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 15.North America Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 16.North America Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 17.North America Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 18.North America Sepsis Diagnostics Market Share (%), By Country, 2017-2031F
• Figure 19.United States Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 20.United States Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 21.United States Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 22.United States Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 23.United States Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 24.United States Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 25.United States Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 26.United States Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 27.Canada Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 28.Canada Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 29.Canada Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 30.Canada Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 31.Canada Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 32.Canada Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 33.Canada Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 34.Canada Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 35.Mexico Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 36.Mexico Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 37.Mexico Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 38.Mexico Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 39.Mexico Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 40.Mexico Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 41.Mexico Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 42.Mexico Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 43.Europe Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 44.Europe Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 45.Europe Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 46.Europe Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 47.Europe Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 48.Europe Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 49.Europe Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 50.Europe Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 51.Europe Sepsis Diagnostics Market Share (%), By Country, 2017-2031F
• Figure 52.Germany Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 53.Germany Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 54.Germany Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 55.Germany Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 56.Germany Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 57.Germany Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 58.Germany Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 59.Germany Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 60.France Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 61.France Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 62.France Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 63.France Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 64.France Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 65.France Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 66.France Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 67.France Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 68.Italy Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 69.Italy Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 70.Italy Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 71.Italy Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 72.Italy Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 73.Italy Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 74.Italy Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 75.Italy Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 76.United Kingdom Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 77.United Kingdom Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 78.United Kingdom Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 79.United Kingdom Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 80.United Kingdom Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 81.United Kingdom Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 82.United Kingdom Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 83.United Kingdom Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 84.Russia Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 85.Russia Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 86.Russia Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 87.Russia Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 88.Russia Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 89.Russia Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 90.Russia Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 91.
• Figure 92.Russia Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 93.Netherlands Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 94.Netherlands Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 95.Netherlands Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 96.Netherlands Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 97.Netherlands Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 98.Netherlands Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 99.Netherlands Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 100.Netherlands Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 101.Spain Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 102.Spain Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 103.Spain Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 104.Spain Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 105.Spain Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 106.Spain Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 107.Spain Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 108.Spain Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 109.Turkey Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 110.Turkey Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 111.Turkey Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 112.Turkey Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 113.Turkey Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 114.Turkey Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 115.Turkey Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 116.Turkey Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 117.Poland Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 118.Poland Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 119.Poland Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 120.Poland Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 121.Poland Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 122.Poland Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 123.Poland Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 124.Poland Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 125.South America Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 126.South America Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 127.South America Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 128.South America Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 129.South America Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 130.South America Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 131.South America Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 132.South America Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 133.South America Sepsis Diagnostics Market Share (%), By Country, 2017-2031F
• Figure 134.Brazil Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 135.Brazil Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 136.Brazil Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 137.Brazil Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 138.Brazil Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 139.Brazil Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 140.Brazil Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 141.Brazil Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 142.Argentina Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 143.Argentina Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 144.Argentina Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 145.Argentina Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 146.Argentina Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 147.Argentina Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 148.Argentina Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 149.Argentina Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 150.Asia-Pacific Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 151.Asia-Pacific Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 152.Asia-Pacific Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 153.Asia-Pacific Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 154.Asia-Pacific Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 155.Asia-Pacific Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 156.Asia-Pacific Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 157.Asia-Pacific Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 158.Asia-Pacific Sepsis Diagnostics Market Share (%), By Country, 2017-2031F
• Figure 159.India Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 160.India Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 161.India Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 162.India Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 163.India Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 164.India Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 165.India Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 166.India Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 167.China Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 168.China Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 169.China Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 170.China Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 171.China Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 172.China Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 173.China Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 174.China Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 175.Japan Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 176.Japan Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 177.Japan Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 178.Japan Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 179.Japan Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 180.Japan Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 181.Japan Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 182.Japan Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 183.Australia Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 184.Australia Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 185.Australia Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 186.Australia Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 187.Australia Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 188.Australia Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 189.Australia Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 190.Australia Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 191.Vietnam Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 192.Vietnam Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 193.Vietnam Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 194.Vietnam Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 195.Vietnam Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 196.Vietnam Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 197.Vietnam Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 198.Vietnam Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 199.South Korea Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 200.South Korea Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 201.South Korea Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 202.South Korea Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 203.South Korea Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 204.South Korea Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 205.South Korea Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 206.South Korea Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 207.Indonesia Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 208.Indonesia Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 209.Indonesia Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 210.Indonesia Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 211.Indonesia Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 212.Indonesia Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 213.Indonesia Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 214.Indonesia Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 215.Philippines Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 216.Philippines Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 217.Philippines Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 218.Philippines Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 219.Philippines Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 220.Philippines Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 221.Philippines Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 222.Philippines Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 223.Middle East & Africa Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 224.Middle East & Africa Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 225.Middle East & Africa Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 226.Middle East & Africa Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 227.Middle East & Africa Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 228.Middle East & Africa Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 229.Middle East & Africa Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 230.Middle East & Africa Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 231.Middle East & Africa Sepsis Diagnostics Market Share (%), By Country, 2017-2031F
• Figure 232.Saudi Arabia Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 233.Saudi Arabia Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 234.Saudi Arabia Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 235.Saudi Arabia Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 236.Saudi Arabia Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 237.Saudi Arabia Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 238.Saudi Arabia Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 239.Saudi Arabia Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 240.UAE Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 241.UAE Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 242.UAE Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 243.UAE Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 244.UAE Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 245.UAE Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 246.UAE Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 247.UAE Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 248.South Africa Sepsis Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 249.South Africa Sepsis Diagnostics Market, By Volume, In Million Units, 2017-2031F
• Figure 250.South Africa Sepsis Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 251.South Africa Sepsis Diagnostics Market Share (%), By Technology, 2017-2031F
• Figure 252.South Africa Sepsis Diagnostics Market Share (%), By Method, 2017-2031F
• Figure 253.South Africa Sepsis Diagnostics Market Share (%), By Test Type, 2017-2031F
• Figure 254.South Africa Sepsis Diagnostics Market Share (%), By Pathogen, 2017-2031F
• Figure 255.South Africa Sepsis Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 256.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 257.By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 258.By Method Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 259.By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 260.By Pathogen Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 261.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 262.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global sepsis diagnostics market is projected to witness a CAGR of 8.7% during the forecast period 2024-2031, growing from USD 0.8 billion in 2023 to USD 1.56 billion in 2031F. The market expansion is supported by increasing investments towards sepsis related research activities, rising cases of sepsis, growing prevalence of infectious diseases, development of advanced diagnostic solutions, and increasing initiatives by various governments to spread awareness about sepsis.

The increasing emphasis towards the development of advanced diagnostic solutions can be attributed to rising number of cases related to sepsis. As per the Center for Disease Control and Prevention (CDC), approximately 1.7 million adults in the United States develop sepsis and roughly 2,70,000 dies from it every year. Various major medical diagnostic companies and startups are actively working towards developing advanced diagnostic solutions that can provide the healthcare providers with rapid and accurate results, reducing their burden.

Various research and development activities are also underway by leading research institutions, supporting the sepsis diagnostics market growth. For instance, Assiut University, Asyut, Egypt, is currently conducting an interventional study to validate the performance of PCT and CRP for early differentiation of IFI from bloodstream infections. They also aim to detect systemic infections at an earlier stage with the help of blood culture and biomarkers. The study is expected to reach conclusion in March 2025.

The rising efforts of various governments to promote awareness about the condition due to increased prevalence, coupled with growing investments towards the enhancement of the healthcare ecosystem, is boosting the market demand. Strategic collaborations and rising investments by major market players to foster the development and commercialization of advanced diagnostic tools is further expected to propel market growth.

Increasing Investments Support Sepsis Diagnostics Market Expansion

Rising investments by the leading market players in the development of advanced diagnostic solutions, due to increasing prevalence of sepsis in different regions across the globe, are bolstering the market expansion. In 2023, Proxim Diagnostics Corporation, an innovative company involved with the development of handheld, point-of care diagnostic devices received investment from BioMerieux SA, one of the global leaders in the field of in vitro diagnostics. With the received funds, Proxim aims to complete the development of their profile system, a fully automated and portable immunodiagnostic device that can run a wide range of multiplexed assays. Proxim is also developing several immunoassays for infectious diseases, sepsis, and cardiology that can provide the same level of precision and sensitivity as tests run on centralized equipment. Such efforts are expected to propel the development of advanced diagnostic solutions that offer rapid generation of test results.

Rising Prevalence of Sepsis Boost Market Demand

The increasing prevalence of sepsis in different regions is expected to offer lucrative growth opportunities to the market. According to the UK Sepsis Trust, 2,45,000 individuals are affected by sepsis in the United Kingdom alone, with approximately 48,000 individuals losing their lives to various sepsis-related illnesses every year. The rise in incidences related to sepsis can be attributed to the expansion of the aging population with high predisposing comorbidities, increased requirement for invasive procedures and medical devices, spread of multi-drug resistant pathogens, and frequent utilization of immunosuppression. The condition usually occurs when the immune system overreacts to the infection caused by parasites, bacteria, viruses, or fungi. The immune system starts attacking the patient's organs, resulting in organ failure.

North America Accounts for a Significant Market Share

North America accounts for a significant share of the market owing to the growing adoption of advanced diagnostic solutions, the increasing prevalence of sepsis, and presence of a well-established healthcare system, along with prominent diagnostic companies in the region. According to recent estimates, Canadian Sepsis Foundation projects that one in eighteen deaths in Canada occur due to complications involving sepsis, making it the twelfth leading cause of death in the country.

In 2023, Cytovale, a United States based medical diagnostics company raised USD 84 million in venture capital funding to roll out their emergency room-focused diagnostics for detecting early cases of sepsis. In August 2023, the company announced the first placement of their IntelliSep testing platform. With it, they aim to offer diagnosis to adults displaying the signs of the infection in less than ten minutes. The investment round was joined by backers, including Global Health Investment Corporation and Sands Capital.

Bacterial Sepsis Anticipated to Account for Significant Market Share

The increasing frequency of various surgical procedures is a key factor supporting the growth of the segment. According to the Global Alliance for Infections in Surgery, after the retrospective review of surgical patients at a medical center in the United States, it was reported that sepsis developed in approximately 3.4% of the nearly 25,500 patients that underwent a surgical procedure over a 3.5-year interval. The growth of the segment is also supported by increasing launch of advanced diagnostic devices for the detection of diseases that are caused by this pathogen.

Meanwhile, fungal sepsis accounts for the second largest share of the market. Usually patients with weak/ compromised immune systems are more susceptible to encounter the disease through various fungal infections.

Hospitals and Clinics Expected to Witness Significant Growth

The growth of the segment can be attributed to growing hospitalization of patients with sepsis and increasing requirement for blood culture tests by in-house hospital and clinic laboratories to identify the type of infection. According to the Center for Disease Control and Prevention, 1 in 3 patients who die in a hospital had sepsis over the course of their hospitalization. The growing awareness about the condition is further bolstering the number of patients that are admitted with sepsis, propelling the requirement for sepsis diagnostic devices and software. The rising investments in the healthcare infrastructure and increasing awareness about the convenience offered by sepsis diagnostic tools to healthcare professionals are further aiding the expansion of the segment.

Future Market Scenario (2024 - 2031F)

Various diagnostic start-ups, key market players, and research organizations are actively working on the development of rapid tests to bypass the requirement of culturing patient samples, provide enhanced determination of the nature of the infection, and improve accuracy. For instance, Inflammatix, a California based biotechnology company involved in the development of rapid point-of-care diagnostic tests, is preparing to launch a thirty-minute blood-based test that could help physicians in detecting sepsis and other acute infections in 2024. The test is expected to aid the healthcare providers in differentiating between viral and bacterial infections, while generating risk scores to determine the likelihood of the patient developing severe diseases in the coming days. The Stanford University Spinout intends to launch the TriVerity Acute Infection and Sepsis Test System in the fourth quarter of 2024.

Key Players Landscape and Outlook

Key participants in the sepsis diagnostic market include Becton, Dickinson & Company, BioMerieux SA, F. Hoffmann-La Roche AG, Luminex Corp., and Thermo Fisher Scientific, Inc. The market expansion is supported by increasing FDA approval for novel diagnostic solutions and rising strategic collaborations for development of end-to-end solutions for diagnosing bloodstream infections.

In 2023, Day Zero Diagnostics, a Boston-based infectious disease diagnostics firm, announced partnership with U.K.-based Oxford Nanopore Technologies. The companies aim to develop an integrated diagnostic system by combining their technologies to combat different infections that may lead to sepsis. According to them, the diagnostic system would offer genomic-based antibiotic susceptibility profiling and same day identification without requiring blood culture. The company will combine the sequencing reads from Nanopore's high-throughput, small-format PromethION 2 Solo and Day Zero Diagnostic's artificial intelligence driven antibiotic susceptibility pipeline and Keynome microbial identification.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Sepsis Diagnostics Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Product
  • 4.2.1.Blood Culture Media
  • 4.2.2.Assay Kits and Reagents
  • 4.2.3.Instruments
  • 4.2.4.Software
• 4.3.By Technology
  • 4.3.1.Microbiology
  • 4.3.2.Molecular Diagnostics
  • 4.3.3.Immunoassays
  • 4.3.4.Flow Cytometry
  • 4.3.5.Others
• 4.4.By Method
  • 4.4.1.Conventional
  • 4.4.2.Automated
• 4.5.By Test Type
  • 4.5.1.Laboratory Tests
  • 4.5.2.Point-of-Care Tests
• 4.6.By Pathogen
  • 4.6.1.Fungal Sepsis
  • 4.6.2.Bacterial Sepsis
    • 4.6.2.1.Gram-positive bacteria
    • 4.6.2.2.Gram-negative bacteria
  • 4.6.3.Viral Sepsis
  • 4.6.4.Others
• 4.7.By End-user
  • 4.7.1.Diagnostic Centers
  • 4.7.2.Hospitals & Clinics
  • 4.7.3.Pathology & Reference Laboratories
  • 4.7.4.Research Laboratories & Academic Institutes
  • 4.7.5.Others
• 4.8.By Region
  • 4.8.1.North America
  • 4.8.2.South America
  • 4.8.3.Europe
  • 4.8.4.Asia-Pacific
  • 4.8.5.Middle East & Africa
• 4.9.By Company Market Share (%), 2023

5.Global Sepsis Diagnostics Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Product
    • 5.1.2.1.Blood Culture Media
    • 5.1.2.2.Assay Kits and Reagents
    • 5.1.2.3.Instruments
    • 5.1.2.4.Software
  • 5.1.3.By Technology
    • 5.1.3.1.Microbiology
    • 5.1.3.2.Molecular Diagnostics
    • 5.1.3.3.Immunoassays
    • 5.1.3.4.Flow Cytometry
    • 5.1.3.5.Others
  • 5.1.4.By Method
    • 5.1.4.1.Conventional
    • 5.1.4.2.Automated
  • 5.1.5.By Test Type
    • 5.1.5.1.Laboratory Tests
    • 5.1.5.2.Point-of-Care Tests
  • 5.1.6.By Pathogen
    • 5.1.6.1.Fungal Sepsis
    • 5.1.6.2.Bacterial Sepsis
    • 5.1.6.2.1.Gram-positive bacteria
    • 5.1.6.2.2.Gram-negative bacteria
    • 5.1.6.3.Viral Sepsis
    • 5.1.6.4.Others
  • 5.1.7.By End-user
    • 5.1.7.1.Diagnostic Centers
    • 5.1.7.2.Hospitals & Clinics
    • 5.1.7.3.Pathology & Reference Laboratories
    • 5.1.7.4.Research Laboratories & Academic Institutes
    • 5.1.7.5.Others
  • 5.1.8.United States*
    • 5.1.8.1.Market Size & Forecast
    • 5.1.8.1.1.By Value
    • 5.1.8.1.2.By Volume
    • 5.1.8.2.By Product
    • 5.1.8.2.1.Blood Culture Media
    • 5.1.8.2.2.Assay Kits and Reagents
    • 5.1.8.2.3.Instruments
    • 5.1.8.2.4.Software
    • 5.1.8.3.By Technology
    • 5.1.8.3.1.Microbiology
    • 5.1.8.3.2.Molecular Diagnostics
    • 5.1.8.3.3.Immunoassays
    • 5.1.8.3.4.Flow Cytometry
    • 5.1.8.3.5.Others
    • 5.1.8.4.By Method
    • 5.1.8.4.1.Conventional
    • 5.1.8.4.2.Automated
    • 5.1.8.5.By Test Type
    • 5.1.8.5.1.Laboratory Tests
    • 5.1.8.5.2.Point-of-Care Tests
    • 5.1.8.6.By Pathogen
    • 5.1.8.6.1.Fungal Sepsis
    • 5.1.8.6.2.Bacterial Sepsis
    • 5.1.8.6.2.1.Gram-positive bacteria
    • 5.1.8.6.2.2.Gram-negative bacteria
    • 5.1.8.6.3.Viral Sepsis
    • 5.1.8.6.4.Others
    • 5.1.8.7.By End-user
    • 5.1.8.7.1.Diagnostic Centers
    • 5.1.8.7.2.Hospitals & Clinics
    • 5.1.8.7.3.Pathology & Reference Laboratories
    • 5.1.8.7.4.Research Laboratories & Academic Institutes
    • 5.1.8.7.5.Others
  • 5.1.9.Canada
  • 5.1.10.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Product
• 6.2.By Technology
• 6.3.By Method
• 6.4.By Test Type
• 6.5.By Pathogen
• 6.6.By End-user
• 6.7.By Region

7.Macro Environment and Industry Structure

• 7.1.Supply Demand Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Patent Landscape
• 9.2.Regulatory Approvals
• 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Becton, Dickinson & Company
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.BioMerieux SA
• 13.3.F. Hoffmann-La Roche AG
• 13.4.Luminex Corp.
• 13.5.Thermo Fisher Scientific, Inc.
• 13.6.Abbott Laboratories
• 13.7.Danaher Corporation
• 13.8.Bruker Corporation
• 13.9.Cerner Corporation
• 13.10.GE Healthcare

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.Strategic Recommendations

15.About Us & Disclaimer